Mismatch repair deficiency assessment by immunohistochemistry: For Lynch syndrome screening and beyond

Hui Li Wong, Michael Christie, Lucy Gately, Jeanne Tie, Belinda Lee, Christine Semira, Sheau Wen Lok, Rachel Wong, Peter Gibbs

Research output: Contribution to journalReview ArticleResearchpeer-review

6 Citations (Scopus)

Abstract

While mismatch repair (MMR) deficiency has been studied extensively, the assessment of MMR status in colorectal and other cancers remains highly relevant, particularly in light of recent data demonstrating that MMR deficiency is a strong predictor for treatment benefit with immune checkpoint inhibitors across multiple tumor types. In colorectal cancer, there is a growing consensus in support of routine MMR testing for Lynch syndrome screening, to inform prognosis and adjuvant chemotherapy use in early stage disease, and to predict response to immunotherapy in advanced disease. Here, we provide a review of the Ventana MMR Immunohistochemistry Panel, which was recently approved by the US FDA for use in Lynch syndrome screening.

Original languageEnglish
Pages (from-to)2725-2739
Number of pages15
JournalFuture Oncology
Volume14
Issue number26
DOIs
Publication statusPublished - Nov 2018
Externally publishedYes

Keywords

  • biomarkers
  • gastrointestinal/colorectal
  • pathology

Cite this

Wong, H. L., Christie, M., Gately, L., Tie, J., Lee, B., Semira, C., Lok, S. W., Wong, R., & Gibbs, P. (2018). Mismatch repair deficiency assessment by immunohistochemistry: For Lynch syndrome screening and beyond. Future Oncology, 14(26), 2725-2739. https://doi.org/10.2217/fon-2018-0319